# 人工智能基因组市场

> 基因组学市场研究报告按应用（药物发现、基因组数据分析、个性化医疗、农业基因组学、诊断）、按技术（机器学习、深度学习、自然语言处理、计算机视觉）、按部署类型（基于云的、本地部署）、按最终用户（制药公司、生物技术公司、研究机构、医疗服务提供者）、按解决方案类型（软件、服务）以及按地区 - 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 17.88%
- **2024:** $ 14.22 Billion
- **2025:** $ 16.76 Billion
- **2035:** $ 86.85 Billion
- **Key Players:** Companies such as Illumina (US), Thermo Fisher Scientific (US), Bristol-Myers Squibb (US), Regeneron Pharmaceuticals (US), GRAIL (US), Freenome (US), Zymergen (US), BenevolentAI (GB), Genomatix (DE) are some of the major participants in the global market.

**Report ID:** MRFR/LS/29504-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** May 14, 2026

**URL:** https://www.marketresearchfuture.com/reports/ai-genomics-market-31278

---

## Market Summary

## **AI in Genomics Market Overview:**

As per MRFR analysis, the AI in Genomics Market Size was estimated at 14.22 (USD Billion) in 2024. The AI in Genomics Market Industry is expected to grow from 16.76 (USD Billion) in 2025 to 73.68 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 17.88% during the forecast period (2025 - 2034).

## **Key AI in Genomics Market Trends Highlighted**

The AI in Genomics Market is witnessing significant growth fueled by advancements in artificial intelligence and its applications in genomic research and personalized medicine. Key market drivers include the increasing demand for precision medicine, where tailored treatments are provided based on an individual's genetic makeup. The ability of AI to analyze vast amounts of genomic data efficiently and accurately enhances drug discovery and diagnostic processes, thereby reducing time to market for new therapies. The continual improvement in machine learning algorithms and data analytics further supports the integration of AI in genomics, making it an indispensable tool for researchers and healthcare providers.

Opportunities in the AI genomics arena are abundant, particularly in the realms of early disease detection and management, drug development, and agricultural genomics. The potential to harness AI-driven insights for genetic modifications and improved crop yields offers promising avenues for innovation. Moreover, the growing trend towards population genomics and biobanking provides a fertile ground for developing AI applications that can analyze genetic correlations across diverse populations. Collaborations between technology firms and research institutions also present opportunities for advancing AI solutions tailored to genomic needs.

Recent trends highlight an increase in investments focused on integrating AI technologies in genomic research, with firms striving to consolidate their positions through mergers and acquisitions. The advent of cloud-based genomic platforms is reshaping data accessibility, allowing for collaborative research and accelerating findings in genomic studies. Furthermore, ethical considerations surrounding gene editing and data privacy are gaining attention, prompting discussions on regulatory frameworks that would support responsible AI use in genomics without stifling innovation. These evolving dynamics underline the transformative potential of AI in genomics, driving a shift towards more personalized, efficient, and informed healthcare solutions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **AI in Genomics Market Drivers**

### Advancements in AI **Technology**

The rapid advancements in artificial intelligence technology are significantly driving the AI in Genomics Market Industry forward. The integration of machine learning algorithms and deep learning techniques has enabled researchers to interpret and analyze vast amounts of genomic data with unprecedented accuracy and efficiency. This evolution in computational power allows for the identification of genetic variants, patterns, and anomalies that were previously undetectable using traditional genomic analysis methods.

As the cost of sequencing decreases and the speed of data processing increases, AI tools can leverage these large datasets to enhance personalized medicine approaches. This means tailored treatments can become a reality, targeting specific genetic profiles, thus improving patient outcomes significantly. Furthermore, AI's ability to continuously learn and adapt contributes to the development of predictive models that can forecast disease susceptibility and treatment responses, revolutionizing the way healthcare is delivered.

The combination of AI and genomics is set to reshape research methodologies, clinical trials, and therapeutic strategies, making this integration a core driver of the AI in Genomics Market. As a result, investments in AI technologies and collaborations among tech companies, research institutions, and healthcare providers are on the rise, ensuring that this driver will continue to have a substantial impact on market growth in the foreseeable future.

### **Growing Demand for Genomic Medicine**

The increasing demand for genomic medicine is a vital driver in the AI in Genomics Market Industry. As awareness about precision medicine grows, patients and healthcare providers are more inclined to seek genomic insights for effective treatment plans. The shift towards personalized healthcare requires advanced genetic understanding, which is only achievable through AI-powered genomic analysis. This trend is propelling investments and innovations aimed at enhancing patient care through tailored therapeutics.

### **Mergers and Partnerships in the Biotechnology Sector**

Strategic mergers and partnerships within the biotechnology sector are strengthening the AI in Genomics Market Industry. These collaborations between established biotech firms and AI technology companies facilitate the exchange of expertise and resources, which enhances the development of genomics-based solutions. By pooling their capabilities, these entities can accelerate research and product development, ultimately pushing market growth.

## **AI in Genomics Market Segment Insights:**

### **AI in Genomics Market Application Insights   **

The AI in Genomics Market is experiencing significant growth, particularly in its Application segment, which is projected to reach substantial valuations by 2032. This growth is largely fueled by advancements in data analytics, an increased emphasis on personalized healthcare, and the need for efficient drug discovery processes. Within the Application segment, the demand for innovative solutions is diversifying into several key sub-segments: Drug Discovery, Genomic Data Analysis, Personalized Medicine, Agrigenomics, and Diagnostics.

Drug Discovery is emerging as a critical area within the AI in Genomics Market, currently valued at 3.5 USD Billion in 2023, it is estimated to escalate to 15.75 USD Billion by 2032.

The integration of AI technologies in drug discovery is streamlining research and development processes, reducing time and costs associated with bringing new drugs to market. Following closely is Genomic Data Analysis, valued at 2.2 USD Billion in 2023 and anticipated to grow to 9.9 USD Billion by 2032. This sub-segment is surged by the increasing availability of genomic data, where AI is being utilized to enhance the extraction of insights from complex datasets, allowing for better interpretation and utilization of genetic information.

Personalized Medicine is another pivotal sub-segment, starting at 2.3 USD Billion in 2023 and projected to reach 10.5 USD Billion in 2032.

The increasing focus on tailoring treatment plans to individual genetic profiles is driving this segment, making use of AI algorithms to analyze patient data to provide personalized therapeutic options. Agrigenomics, crucial for improving food security and agricultural efficiency, is projected to grow from 1.3 USD Billion in 2023 to 6.0 USD Billion in 2032, as AI helps in the genetic modification and yield improvement of crops and livestock.

Lastly, Diagnostics, which focuses on precise disease detection, is valued at 0.93 USD Billion in 2023 and expected to increase to 3.85 USD Billion by 2032, with AI facilitating the interpretation of genomic data to identify abnormalities swiftly.

The interplay of these sub-segments reflects the overall market growth trends, revealing a significant opportunity for expansion in the AI in Genomics Market as the healthcare landscape evolves. Market growth is driven by technological advancements, increasing investments in genomics, rising demand for precision and personalized healthcare, and a greater understanding of genomic data. However, challenges such as data privacy concerns and the need for regulatory approvals may impact the pace of growth. Overall, the AI in Genomics Market segmentation in Applications illustrates a dynamic landscape enriched with opportunities for innovative developments across various industries including healthcare, agriculture, and diagnostics.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **AI in Genomics Market Technology Insights   **

Among the various sub-segments, Machine Learning is emerging as a critical driver, primarily facilitating Drug Discovery, which is forecasted to grow from 3.5 USD Billion in 2023 to 15.75 USD Billion by 2032. Natural Language Processing (NLP) is also gaining traction, especially in genomics data interpretation and personalized medicine, which is expected to increase in value from 2.3 USD Billion in 2023 to 10.5 USD Billion by 2032. Deep Learning technologies are set to enhance Genomic Data Analysis, moving from 2.2 USD Billion in 2023 to 9.9 USD Billion a decade later.

Additionally, Computer Vision applications in Agrigenomics, currently valued at 1.3 USD Billion in 2023, are projected to reach 6.0 USD Billion by 2032. As the AI in Genomics Market continues to evolve, trends in advanced analytics, precision health, and automation present both challenges and opportunities for stakeholders, influencing the overall AI in Genomics Market Statistics and industry dynamics.

### **AI in Genomics Market Deployment Type Insights   **

The Deployment Type segment of the AI in Genomics Market is experiencing significant growth as the market is projected to reach a valuation of 45.0 USD Billion by 2032, up from 10.23 USD Billion in 2023. This growth is driven by an expected CAGR of 17.88% from 2025 to 2034. The Cloud-Based deployment is expected to lead the market due to its scalability, cost-effectiveness, and ability to handle large datasets, while On-Premises solutions are preferred by organizations with stringent data security and compliance requirements.

Among the various sub-segments, Drug Discovery is anticipated to showcase remarkable growth, with market values ascending from 3.5 USD Billion in 2023 to 15.75 USD Billion by 2032.

### **AI in Genomics Market End User Insights   **

The AI in Genomics Market is poised for substantial growth, with its overall market revenue expected to reach 45.0 USD Billion by 2032, up from 10.23 USD Billion in 2023, indicating a marked increase driven by various end user segments. Key players in this market include Pharmaceutical Companies, Biotechnology Firms, Research Institutions, and Healthcare Providers, all leveraging AI technologies to enhance their genomic capabilities.

The Drug Discovery sub-segment stands out, projected to grow from 3.5 USD Billion in 2023 to 15.75 USD Billion in 2032, as companies seek innovative ways to expedite the development of new therapies.Overall, the market dynamics exhibit a robust trajectory for the AI in Genomics Market, accentuated by the transformative potential of AI in genomic applications.

### **AI in Genomics Market Solution Type Insights   **

The AI in Genomics Market is projected to experience substantial growth driven by its diverse solution types, including software and services. As the market is expected to be valued at 10.23 USD Billion in 2023 and grow to approximately 45.0 USD Billion by 2032, this indicates a significant opportunity within the realm of genomic data analysis and application. Specifically, the software segment, which encompasses critical applications for drug discovery, genomic data analysis, personalized medicine, agrigenomics, and diagnostics, shows promising potential.

Furthermore, services associated with these solutions are set to expand, providing insights and expert assistance in navigating complex genomic landscapes.

### **AI in Genomics Market Regional Insights**

North America is poised to dominate the market, mainly driven by high investments in genomic research and advanced healthcare infrastructure. In contrast, Europe is also showing substantial potential, with innovations in personalized medicine leading to a rise in its market share. The APAC region is emerging rapidly, buoyed by an increase in healthcare spending and technological advancements in genomics. South America and MEA, while currently smaller sub-regions in the AI in Genomics Market revenue, are witnessing an increased focus on genetic research and diagnostics, facilitating growth opportunities ahead.

Within these regions, sub-segments such as Drug Discovery, projected to be valued at 15.75 USD Billion by 2032, and Genomic Data Analysis, expected to reach 9.9 USD Billion by 2032, are set to be significant contributors to the overall market expansion. Personalized Medicine is another critical area, with a growth forecast to reach 10.5 USD Billion by 2032, reflecting the intensifying trend toward individualized healthcare solutions.

The continued evolution of diagnostic technologies and their applications in Agrigenomics, valued at 6.0 USD Billion by 2032, also represents an important segment within the AI in Genomics Market segmentation, revealing the comprehensive nature of this industry amidst various regional dynamics and emerging trends.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **AI in Genomics Market Key Players And Competitive Insights:**

The AI in Genomics Market is evolving rapidly, driven by advancements in artificial intelligence technologies and the increasing volume of genomic data. This market encompasses a variety of applications ranging from drug discovery, personalized medicine, genetic testing, and data analysis, resulting in a competitive landscape that features numerous players vying for technological superiority and market share. Key factors influencing the dynamics of this market include innovation in machine learning algorithms, enhanced computational power, regulatory challenges, and the increasing awareness of genomics in healthcare.

Companies in this field are exploring collaborative efforts, partnerships, and mergers and acquisitions to enhance their product offerings and expand their reach, resulting in a constant reshuffling of competitive positioning.

DnaNudge stands out in the AI in Genomics Market with its unique approach to integrating genomics and consumer health. The company's strength lies in its proprietary technology that enables real-time genetic testing and personalized dietary recommendations, allowing users to make informed lifestyle choices based on their genetic profiles. DnaNudge’s innovative platform leverages artificial intelligence to interpret complex genomic data, resulting in actionable insights that resonate with health-conscious consumers and healthcare professionals alike.

The company is well-positioned in the market due to its user-friendly applications and the rising trend of personalized medicine. DnaNudge's focus on consumer engagement and empowerment through genetic insights strengthens its competitive advantage, making it a notable player in the genomic landscape.BioSymetrics operates within the AI in Genomics Market, specializing in AI-driven solutions for understanding complex biological data. This company focuses on combining clinical, genomic, and biometric data to develop predictive models that can enhance drug discovery processes and facilitate targeted therapeutic strategies. 

BioSymetrics has established a unique data architecture that allows for the integration and analysis of multi-modal data, which is essential in the personalized medicine arena. The strength of BioSymetrics lies in its cutting-edge algorithms and analytical capabilities that streamline the translation of genomic data into clinical applications. The company’s commitment to innovation and a deep focus on machine learning techniques empower it to deliver valuable insights to researchers and healthcare providers, placing BioSymetrics as a competitive entity in the ever-growing AI genomics space.

**Key Companies in the AI in Genomics Market Include:**

- DnaNudge
- **[BioSymetrics](https://www.biosymetrics.com/)**
- Invitae Corporation
- BenevolentAI
- BGI Genomics
- Zymo Research
- Nference
- Deep Genomics
- Illumina
- WuXi AppTec
- Genomatix GmbH
- Thermo Fisher Scientific
- Fabric Genomics
- Ginkgo BioWorks

## Ai Genomics Market Industry Developments

- **Q2 2024: Illumina and NVIDIA Collaborate to Accelerate AI Genomics Analysis** Illumina announced a partnership with NVIDIA to integrate NVIDIA's AI computing platform into Illumina's genomics analysis workflows, aiming to speed up and scale genomic data interpretation for research and clinical applications.
- **Q2 2024: Fabric Genomics Raises $30 Million in Series C Funding to Advance AI-Driven Genomic Interpretation** Fabric Genomics secured $30 million in Series C funding to expand its AI-powered genomic interpretation platform, supporting clinical diagnostics and precision medicine initiatives.
- **Q2 2024: Tempus Announces Acquisition of AI Genomics Startup Pangea Biomed** Tempus, a leader in AI-driven precision medicine, acquired Pangea Biomed, an AI genomics startup, to enhance its oncology and rare disease genomics capabilities.
- **Q3 2024: Oxford Nanopore Technologies and Microsoft Partner to Develop AI Genomics Tools** Oxford Nanopore Technologies entered a strategic partnership with Microsoft to co-develop AI-powered tools for real-time genomic data analysis, targeting healthcare and research markets.
- **Q3 2024: Grail Launches New AI-Enabled Genomic Cancer Screening Test** Grail announced the commercial launch of a new AI-enabled genomic test designed to detect multiple types of cancer from a single blood draw, leveraging advanced machine learning algorithms.
- **Q3 2024: SOPHiA GENETICS Expands AI Genomics Platform to Asia Through Partnership with BGI** SOPHiA GENETICS formed a partnership with BGI to expand its AI-powered genomics analytics platform into Asian markets, aiming to accelerate adoption in clinical and research settings.
- **Q4 2024: Deep Genomics Raises $100 Million Series D to Advance AI Drug Discovery Platform** Deep Genomics closed a $100 million Series D funding round to further develop its AI-driven platform for genomic drug discovery and expand its therapeutic pipeline.
- **Q4 2024: PathAI Receives FDA Clearance for AI Genomics Companion Diagnostic** PathAI announced FDA clearance for its AI-powered genomics companion diagnostic, enabling more precise patient selection for targeted cancer therapies.
- **Q1 2025: Celsius Therapeutics Raises $75 Million Series B to Scale AI Genomics Platform** Celsius Therapeutics raised $75 million in Series B funding to scale its AI-driven genomics platform focused on autoimmune disease and oncology research.
- **Q1 2025: DNAnexus Launches AI-Enhanced Genomics Data Platform for Biopharma** DNAnexus launched a new AI-enhanced genomics data platform designed to support biopharmaceutical companies in large-scale genomic data analysis and drug development.
- **Q2 2025: 23andMe Appoints New Chief AI Officer to Lead Genomics Innovation** 23andMe appointed a Chief AI Officer to spearhead the company's efforts in integrating artificial intelligence into its consumer genomics and health research initiatives.
- **Q2 2025: Helix Opens New AI Genomics Research Facility in San Diego** Helix announced the opening of a new research facility in San Diego dedicated to advancing AI-powered genomics research and accelerating the development of precision medicine solutions.

## **AI in Genomics Market Segmentation Insights**

### **AI in Genomics Market Application Outlook**

- Drug Discovery
- Genomic Data Analysis
- Personalized Medicine
- Agrigenomics
- Diagnostics

### **AI in Genomics Market Technology Outlook**

- Machine Learning
- Deep Learning
- Natural Language Processing
- Computer Vision

### **AI in Genomics Market Deployment Type Outlook**

- Cloud-Based
- On-Premises

### **AI in Genomics Market End User Outlook**

- Pharmaceutical Companies
- Biotechnology Firms
- Research Institutions
- Healthcare Providers

### **AI in Genomics Market Solution Type Outlook**

- Software
- Services

### **AI in Genomics Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### 个性化医疗需求上升

基因组学市场中的人工智能受到个性化医疗需求上升的显著影响。随着医疗保健向量身定制的治疗方案转变，基因组数据在理解个体患者档案中发挥着至关重要的作用。这一趋势在越来越多专注于基因组学基础疗法的临床试验中得到了体现。根据最近的估计，个性化医疗市场预计到2030年将达到2万亿美元，其中相当一部分归因于基因组创新。人工智能技术促进了基因组数据的分析，使医疗保健提供者能够制定定制的治疗策略。因此，人工智能在基因组学中的整合正变得对旨在提升药物开发过程和改善患者结果的制药公司至关重要。

### 协作研究倡议的出现

基因组学市场中的人工智能正受到协作研究倡议的影响。学术机构、医疗保健组织和科技公司之间的合作伙伴关系正在促进基因组学的创新。这些合作旨在利用人工智能技术增强数据共享和分析能力。例如，将基因组数据与临床信息相结合的倡议正在为理解复杂疾病的突破铺平道路。这种协作方法可能会加速基于人工智能的基因组学解决方案的发展，因为多样的专业知识汇聚在一起，解决紧迫的挑战。这一趋势不仅提高了研究的质量，还促进了研究成果向临床应用的转化，从而推动基因组学市场中人工智能的增长。

### 机器学习算法的进展

基因组学市场中的人工智能正在经历一波增长，这得益于机器学习算法的进步。这些算法增强了分析复杂基因组数据的能力，从而带来了更准确的预测和洞察。例如，深度学习技术的整合在识别与疾病相关的遗传变异方面显示出了希望。因此，预计该市场在未来五年将以约30%的复合年增长率增长。这一增长受到对精准医疗日益增长的需求的推动，而精准医疗在很大程度上依赖于基因组数据分析。此外，这些算法高效处理庞大数据集的能力可能会吸引来自公共和私营部门的投资，进一步推动基因组学市场中的人工智能发展。

### 增加对基因组研究的投资

基因组学市场中的人工智能正在受益于对基因组研究的投资增加。各国政府和私人实体正在分配大量资金，以探索基因组学在农业、医疗保健和生物技术等各个领域的潜力。例如，基因组研究计划的资金已显著增加，近年来的投资超过了100亿美元。这一资金的涌入促进了研究人员之间的创新和合作，导致了基因组学中新型人工智能应用的发展。因此，随着新技术的出现，市场可能会扩大，从而实现更高效的数据分析和解读。人工智能与基因组学之间的协同作用预计将为研究和开发开辟新的途径，进一步巩固该行业的增长轨迹。

### 基因组测序技术的日益普及

基因组学市场中的人工智能正在见证基因组测序技术的日益普及。随着测序成本的持续下降，越来越多的机构将这些技术整合到他们的研究和临床实践中。基因组测序市场预计到2026年将达到250亿美元，这得益于测序方法的进步和基因组数据的日益可用。人工智能在分析测序生成的大量数据中发挥着关键作用，使研究人员能够得出有意义的见解。这一趋势可能会提高基因组研究的效率，加快个性化医学和疾病预防领域的发现步伐。人工智能与基因组测序之间的合作预计将重新定义基因组学研究的格局。

## Future Outlook

基因组学市场的人工智能预计将在2024年至2035年间以17.88%的复合年增长率增长，推动因素包括数据分析、个性化医疗和基因组研究的进步。

**New opportunities:**

- 基于人工智能的基因组数据分析平台的开发 人工智能在精准医疗工作流程中的整合 基于人工智能的遗传疾病预测模型的创建

到2035年，基因组学市场中的人工智能预计将成为医疗创新的关键领域。

## Segment Insights

### 按应用：药物发现（最大）与个性化医疗（增长最快）

在基因组学市场的人工智能应用领域，各个细分市场在行业中扮演着不同的角色。药物发现目前占据最大的市场份额，得益于对人工智能技术的重大投资，这些技术简化了药物开发过程，从而加快了上市时间。相反，个性化医疗正在获得动力，因为它利用人工智能根据基因组数据量身定制治疗方案，反映出消费者对定制医疗解决方案日益增长的需求。

药物发现（主导）与个性化医疗（新兴）

药物发现因其成熟的方法论和大量专注于增强研究与开发的资金而在基因组学市场中占据主导地位。人工智能技术正在通过早期预测药物的有效性和安全性来彻底改变这一领域。另一方面，个性化医疗是一个新兴领域，其特点是根据个体基因组信息量身定制健康解决方案的创新方法。得益于人工智能的进步，它显著改善了患者的治疗结果，并与日益向个性化医疗的转变相一致，使其成为一个有吸引力的投资和研究领域。

### 按技术：机器学习（最大）与深度学习（增长最快）

在基因组学市场的人工智能领域，技术细分的分布显示，机器学习占据了最大的市场份额，这归因于其成熟的基础和在基因组数据分析中的广泛应用。它使研究人员能够快速发现大型数据集中复杂的模式。深度学习虽然是一项较新的创新，但由于其处理非结构化数据和生成以前无法获得的洞察的卓越能力，正在获得越来越多的关注。随着算法的改进和计算能力的提升，这一细分市场正在迅速扩展，成为下一代基因组学能力的核心参与者。这些技术的增长趋势受到计算能力进步和遗传数据量增加的推动。这些技术的整合使个性化医疗和先进的基因组编辑成为可能，增强了药物发现过程。随着生物技术公司对基因组学研究的投资持续激增，对机器学习和深度学习应用的需求只会增加。此外，这些技术与数据收集技术创新之间的共生关系有望进一步加速它们的采用。

技术：机器学习（主导）与深度学习（新兴）

机器学习已确立其在基因组学市场人工智能中的主导地位，促进了从预测建模到基因组映射的众多应用。其框架允许高效处理大规模基因组数据，这与现有的生物知识相关联，以预测结果。相反，深度学习被认为是一项新兴技术，代表了向先进神经网络架构的转变，这些架构能够识别基因组序列中的复杂模式。这个不断增长的细分市场的特点是其提高基因表达分析和疾病预测准确性的能力。随着基因组与表型相关性研究的不断发展，这两个细分市场将在塑造治疗路径和患者结果方面发挥关键作用。

### 按部署类型：基于云的（最大）与本地部署（增长最快）

在基因组学市场的人工智能领域，部署类型细分市场主要由基于云的解决方案构成，这些解决方案因其可扩展性、可访问性和成本效益而巩固了其作为最大细分市场的地位。这些解决方案使研究人员和医疗专业人员能够利用庞大的计算资源，而无需承担与物理硬件相关的前期成本。尽管本地部署在市场份额上较小，但在对数据安全和合规性要求严格的组织中正逐渐获得关注，因为他们更倾向于在自己的基础设施中控制敏感的基因组数据。

部署类型：基于云的（主导）与本地部署（新兴）

云端部署在基因组学市场中的特点是能够提供灵活、可扩展的资源，以满足基因研究和分析的动态计算需求。这种部署方式允许用户从任何地方访问强大的人工智能工具和大型数据集，促进全球研究人员之间的合作。另一方面，内部部署解决方案正在成为优先考虑数据安全和隐私的机构的可行选择，因为这些设置提供了对数据处理和合规性的更大控制。这些组织正越来越多地投资于内部基础设施，以适应需要将敏感基因组数据保留在安全本地环境中的特定用例，从而推动该细分市场的快速增长。

### 按最终用户：制药公司（最大）与医疗服务提供者（增长最快）

在基因组学市场中，制药公司占据了最大的市场份额，利用人工智能技术改善药物发现和开发过程。它们利用基因组数据来量身定制治疗方案，从而实现更高效和有效的疗法。同时，研究机构和生物技术公司也发挥着重要作用，但它们的市场份额相对较小，表明制药公司在该领域的集中主导地位。医疗服务提供者作为增长最快的细分市场，正越来越多地采用人工智能技术来增强患者护理、个性化治疗和优化运营效率。基因组学的进步和人工智能的整合也促进了医疗服务提供者与基因组研究人员之间的合作，创造了一个以创新和以患者为中心的方法驱动的生态系统。

医疗服务提供者（主导）与生物技术公司（新兴）

医疗服务提供者在基因组学市场中占据主导地位，因为他们越来越多地采用先进的基因组技术来改善患者的治疗效果。他们对个性化医疗和高效护理交付的承诺推动了人工智能的创新应用案例，如预测分析和基因组数据解读。相反，生物技术公司代表了一种新兴力量，利用人工智能加速药物发现和开发过程。虽然他们的市场份额可能不及医疗服务提供者，但他们灵活的运营和对新型治疗药物的关注使他们在市场中成为关键参与者，随着技术与生物学之间的合作不断发展，他们有潜力实现显著增长。

### 按解决方案类型：软件（最大）与服务（增长最快）

在基因组学市场中，解决方案类型细分主要由软件主导，因其在数据分析和基因组洞察解读中的重要作用而占据了显著份额。软件解决方案提供了一系列功能，从机器学习算法到可视化工具，使其对基因组研究人员和医疗服务提供者都极为宝贵。服务代表了增长最快的细分市场，因为组织寻求专家咨询和实施支持，以有效地将人工智能技术整合到其基因组工作流程中。

解决方案类型：软件（主导）与服务（新兴）

人工智能在基因组学市场中的软件解决方案被认为是主导力量，提供数据管理和分析的基本工具。领先的软件产品包括利用先进算法的平台，以促进基因数据分析、预测建模和个性化医疗策略。相反，服务部门由于对支持服务的需求不断增加而迅速崛起，包括实施、培训和技术支持，因为组织在应对人工智能集成的复杂性时需要这些服务。这一增长是由对专业知识和专业技能的需求推动的，以增强现有基因组系统的能力并最大化人工智能技术的好处。

## Regional Market Share Analysis

北美市场即将主导，主要受益于对基因组研究和先进医疗基础设施的高额投资。相比之下，欧洲也展现出相当大的潜力，个性化医疗的创新使其市场份额上升。亚太地区正在迅速崛起，得益于医疗支出的增加和基因组技术的进步。南美和中东非洲虽然目前在 人工智能在基因组学市场 收入中占比较小，但正在加大对基因研究和诊断的关注，促进未来的增长机会。

在这些地区，药物发现等子细分市场预计到2032年将达到157.5亿美元，基因组数据分析预计到2032年将达到99亿美元，这些都将成为整体市场扩展的重要贡献者。个性化医疗是另一个关键领域，预计到2032年将达到105亿美元，反映出个性化医疗解决方案日益增强的趋势。

诊断技术及其在农业基因组学中的应用持续演变，预计到2032年将达到60亿美元，这也是 人工智能在基因组学市场 细分中的一个重要部分，揭示了在各种区域动态和新兴趋势中该行业的综合特性。

来源：初步研究，二次研究，_市场研究未来_数据库和分析师评审

## Competitive Benchmarking

基因组学市场中的人工智能正在迅速发展，受到人工智能技术进步和基因组数据量增加的推动。该市场涵盖了从药物发现、个性化医疗、基因检测到数据分析等多种应用，形成了一个竞争激烈的格局，众多参与者争夺技术优势和市场份额。影响该市场动态的关键因素包括机器学习算法的创新、计算能力的增强、监管挑战以及对基因组学在医疗保健中日益增长的认识。

该领域的公司正在探索合作努力、伙伴关系以及并购，以增强其产品供应并扩大其影响力，导致竞争定位的不断重组。

DnaNudge在基因组学市场中脱颖而出，其独特的方法将基因组学与消费者健康相结合。该公司的优势在于其专有技术，能够实时进行基因检测并提供个性化的饮食建议，使用户能够根据其基因特征做出明智的生活方式选择。DnaNudge的创新平台利用人工智能来解读复杂的基因组数据，从而产生与健康意识强的消费者和医疗专业人士产生共鸣的可行见解。

由于其用户友好的应用程序和个性化医疗的上升趋势，该公司在市场中处于良好位置。DnaNudge通过基因见解增强消费者参与和赋权的重点，巩固了其竞争优势，使其成为基因组学领域的一个显著参与者。BioSymetrics在基因组学市场中运营，专注于理解复杂生物数据的人工智能驱动解决方案。该公司专注于结合临床、基因组和生物特征数据，开发可以增强药物发现过程并促进靶向治疗策略的预测模型。

BioSymetrics建立了独特的数据架构，允许多模态数据的集成和分析，这在个性化医疗领域至关重要。BioSymetrics的优势在于其尖端算法和分析能力，能够简化基因组数据转化为临床应用的过程。该公司对创新的承诺以及对机器学习技术的深度关注，使其能够为研究人员和医疗提供者提供有价值的见解，使BioSymetrics在不断增长的人工智能基因组学领域中成为一个具有竞争力的实体。

## Recent News & Developments

- **2024年第二季度：Illumina与NVIDIA合作加速AI基因组分析** Illumina宣布与NVIDIA建立合作伙伴关系，将NVIDIA的AI计算平台整合到Illumina的基因组分析工作流程中，旨在加快和扩展基因组数据的解释，以支持研究和临床应用。
- **2024年第二季度：Fabric Genomics获得3000万美元C轮融资以推进AI驱动的基因组解释** Fabric Genomics获得3000万美元C轮融资，以扩展其AI驱动的基因组解释平台，支持临床诊断和精准医疗计划。
- **2024年第二季度：Tempus宣布收购AI基因组初创公司Pangea Biomed** Tempus，一家领先的AI驱动精准医疗公司，收购了AI基因组初创公司Pangea Biomed，以增强其在肿瘤学和罕见疾病基因组方面的能力。
- **2024年第三季度：Oxford Nanopore Technologies与微软合作开发AI基因组工具** Oxford Nanopore Technologies与微软建立战略合作伙伴关系，共同开发用于实时基因组数据分析的AI驱动工具，目标是医疗保健和研究市场。
- **2024年第三季度：Grail推出新的AI启用基因组癌症筛查测试** Grail宣布商业推出一种新的AI启用基因组测试，旨在通过一次抽血检测多种类型的癌症，利用先进的机器学习算法。
- **2024年第三季度：SOPHiA GENETICS通过与BGI的合作将AI基因组平台扩展至亚洲** SOPHiA GENETICS与BGI建立合作伙伴关系，将其AI驱动的基因组分析平台扩展到亚洲市场，旨在加速在临床和研究环境中的采用。
- **2024年第四季度：Deep Genomics获得1亿美元D轮融资以推进AI药物发现平台** Deep Genomics完成1亿美元D轮融资，以进一步开发其AI驱动的基因组药物发现平台，并扩展其治疗管线。
- **2024年第四季度：PathAI获得FDA批准用于AI基因组伴随诊断** PathAI宣布获得FDA批准，其AI驱动的基因组伴随诊断，能够为靶向癌症疗法提供更精确的患者选择。
- **2025年第一季度：Celsius Therapeutics获得7500万美元B轮融资以扩展AI基因组平台** Celsius Therapeutics获得7500万美元B轮融资，以扩展其专注于自身免疫疾病和肿瘤研究的AI驱动基因组平台。
- **2025年第一季度：DNAnexus推出AI增强基因组数据平台以支持生物制药** DNAnexus推出新的AI增强基因组数据平台，旨在支持生物制药公司进行大规模基因组数据分析和药物开发。
- **2025年第二季度：23andMe任命新首席AI官以领导基因组创新** 23andMe任命首席AI官，负责推动公司在消费者基因组和健康研究项目中整合人工智能的努力。
- **2025年第二季度：Helix在圣地亚哥开设新的AI基因组研究设施** Helix宣布在圣地亚哥开设新的研究设施，专注于推进AI驱动的基因组研究，加速精准医疗解决方案的开发。

## Report Scope

| 2024年市场规模 | 142.2（十亿美元） |
| --- | --- |
| 2025年市场规模 | 167.6（十亿美元） |
| 2035年市场规模 | 868.5（十亿美元） |
| 年复合增长率（CAGR） | 17.88%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 主要公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 主要市场机会 | 先进机器学习算法的集成增强了基因组数据分析和个性化医疗。 |
| 主要市场动态 | 人工智能在基因组学中的日益集成增强了精准医疗并加速了药物发现过程。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 到2035年，人工智能在基因组学中的市场估值预计是多少？**
A: 到2035年，基因组学市场中的人工智能预计将达到868.5亿美元的估值。

**Q: 2024年基因组学中人工智能的市场估值是多少？**
A: 在2024年，基因组学市场中的人工智能估值为142.2亿美元。

**Q: 2025年至2035年，基因组学领域人工智能的预期CAGR是多少？**
A: 在2025年至2035年的预测期内，基因组学领域人工智能市场的预期CAGR为17.88%。

**Q: 到2035年，哪个应用领域预计将拥有最高的估值？**
A: 基因组数据分析部门预计到2035年将达到211.2亿美元。

**Q: 推动基因组学市场人工智能的主要技术是什么？**
A: 机器学习和深度学习是领先的技术，预计到2035年，分别将达到300亿美元和250亿美元的估值。

**Q: 在基因组市场细分中，AI的部署类型如何比较？**
A: 预计到2035年，基于云的部署将占主导地位，预计估值为480亿美元，而本地部署的估值为388.5亿美元。

**Q: 到2035年，预计哪个最终用户细分市场将增长最多？**
A: 预计制药公司将显著增长，到2035年达到300亿美元的估值。

**Q: 在基因组学市场中，人工智能软件解决方案的预计增长是多少？**
A: 预计到2035年，软件解决方案将达到300亿美元，显示出强劲的增长。

**Q: 基因组学市场中的关键参与者是谁？**
A: 主要参与者包括Illumina、Thermo Fisher Scientific、百时美施贵宝和Regeneron Pharmaceuticals。

**Q: 到2035年，诊断应用领域的预计估值是多少？**
A: 诊断应用程序领域预计到2035年将达到176.5亿美元的估值。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/ai-genomics-market-31278*